Table of Content

Antimicrobial Resistance - Strategic Situation Analysis & Impact of COVID-19

  • Guide for Executives, Marketing, Sales and Business Development Staff 
  • Guide for Management Consultants and Investment Advisors 

1. Introduction and Market Definition 
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size 
1.3 Methods and Sources 
1.3.1 Authors
1.3.2 Sources 
1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics 
1.4.2 U.S. Pharmaceutical Spending 

2. Overview of a Dynamic Market 
2.1 Market Players - Roles & Impacts 
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic 
2.1.3 Contract Research and Manufacturing 
2.1.4 In Vitro Diagnostics Industry 
2.1.5 Drug Marketing Companies 
2.1.6 Biotechnology Companies 
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance 
2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes 
2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer 
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Diagnostic Technology Development Opportunities
3.2.1 What’s Wrong with Microbiology 
3.2.2 The Features Battleground of Infectious Disease Diagnostics 
3.2.3 Multiplex vs. POC/Rapid 
3.2.4 The Miracle of Genetics 
3.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation 
3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing. 
3.2.7 Markers of Resistance
3.2.8 What Happens to the Microbiology Lab?

4. Antibiotic Resistance Diagnostics Recent Developments 
4.1 Antibiotic Resistance Recent Developments
4.1.1 Importance of These Developments 
4.1.2 How to Use This Section 

  • Campylobacter strains exchange genes
  • Disinfection spreads antimicrobial resistance
  • Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic Platform 
  • Illumina, IDbyDNA Flesh Out Sequencing-Based Respiratory Tests
  • Accelerate Diagnostics Announces Expansion of Antimicrobial Sensitivity Testing 101
  • Rapid diagnostics, antimicrobial stewardship linked to quicker time to optimal antibiotics
  • Visby Medical Wins AMR Diagnostic Competition 
  • DNAe Technology Successfully Detects SARS-CoV-2 Sequences 
  • Infections with foodborne bacteria becoming harder to treat 
  • Dust is sharing antibiotic resistance genes 
  • Report predicts drug resistance likely to kill 400,000
  • New method to test for infection resistance. 
  • Qiagen launches AMR database 
  • Antibiotic resistance test for gonorrhea gets FDA breakthrough 
  • Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics 
  • OpGen to File First 510(k) for AMR Gene Panel 
  • Curetis’ Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR 
  • GeneCapture to determine antibiotic sensitivity in an automated rapid portable device 
  • Quick identification of multidrug-resistant pathogens 
  • OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
  • Metagenomics Enables Researchers to Uncover Drug Resistance Genes 
  • Rapid detection of multi-drug-resistant bacteria
  • High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges 
  • New solution for diagnosing antibiotic-resistant bacteria 
  • MALDI-TOF - Results in Minutes not Days
  • CRISPR Tool Used to Uncover Infections
  • Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
  • BD, Check-Points Receive CE Mark for Resistant Organism Screening Test 
  • OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
  • Hospital Plumbing Harbors Antibiotic Resistant Bacteria
  • Curetis Gets Singapore Approval for Pneumonia Test 
  • PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
  • Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies 

5. Key AMR Diagnostics Companies 

  • 1928 Diagnostics 
  • Abbott Diagnostics 
  • Accelerate Diagnostics 
  • Beckman Coulter Diagnostics 
  • Becton, Dickinson and Company 
  • Binx Health 
  • bioMérieux Diagnostics 
  • Bio-Rad Laboratories, Inc. 
  • Cepheid (now Danaher)
  • Curetis N.V. / Curetis GmbH 
  • Day Zero Diagnostics. 
  • Enzo Life Sciences, Inc. 
  • Eurofins Scientific 
  • Fusion Genomics 
  • GeneFluidics 
  • Great Basin Corporation
  • Hutman Diagnostics 
  • Inflammatix 
  • Linear Diagnostics 
  • Millipore Sigma 
  • Ortho Clinical Diagnostics
  • Perkin Elmer 
  • Roche Molecular Diagnostics
  • SeLux Diagnostics 
  • Sense Biodetection
  • Siemens Healthineers
  • Sysmex 
  • Thermo Fisher Scientific Inc

6. The Global Market for Antimicrobial Resistance Diagnostics
6.1 Global Market Overview by Country
6.1.1 Table - Global Market by Country 
6.1.2 Chart - Global Market by Country 
6.2 Global Market by Technology - Overview 
6.2.1 Table - Global Market by Pathogen
6.2.2 Chart - Global Market by Pathogen - Base/End Year Comparison 
6.2.3 Chart - Global Market by Pathogen - Base Year
6.2.4 Chart - Global Market by Pathogen - End Year 
6.2.5 Chart - Global Market by Pathogen - Share by Year
6.2.6 Chart - Global Market by Pathogen - Segment Growth 
6.3 Global Market by Technology - Overview 
6.3.1 Table - Global Market by Technology
6.3.2 Chart - Global Market by Technology - Base/End Year Comparison 
6.3.3 Chart - Global Market by Technology - Base Year
6.3.4 Chart - Global Market by Technology - End Year 
6.3.5 Chart - Global Market by Technology - Share by Year 
6.3.6 Chart - Global Market by Technology - Segment Growth 

7. Global Antibiotic Resistance Diagnostic Markets - By Pathogen 
7.1 Drug Resistant Streptococcus Pneumoniae - DRSP 
7.1.1 Table DRSP - by Country
7.1.2 Chart - DRSP Growth
7.2 Drug Resistant Campylobacter - DRC
7.2.1 Table DRC - by Country 
7.2.2 Chart - DRC Growth 
7.3 Clostridium Difficile - CD
7.3.1 Table CD - by Country 
7.3.2 Chart - CD Growth
7.4 Methicillin Resistant Staphylococcus Aureus - MRSA 
7.4.1 Table MRSA - by Country 
7.4.2 Chart - MRSA Growth
7.5 Drug Resistant Neisseria Gonorrhoeae - DRNG 
7.5.1 Table DRNG - by Country 
7.5.2 Chart - DRNG Growth
7.6 Drug Resistant Salmonella - DRNTS 
7.6.1 Table DRNTS - by Country 
7.6.2 Chart - DRNTS Growth

8. Global Antibiotic Resistance Diagnostic Markets - by Technology 
8.1 Microbiology Culture
8.1.1 Table Culture - by Country 
8.1.2 Chart - Culture Growth
8.2 Immunoassay 
8.2.1 Table Immunoassay - by Country 
8.2.2 Chart - Immunoassay Growth 
8.3 PCR 
8.3.1 Table PCR - by Country
8.3.2 Chart - PCR Growth
8.4 NGS 
8.4.1 Table NGS - by Country 
8.4.2 Chart - NGS Growth 
8.5 Mass Spectrometry - MS 
8.5.1 Table MS - by Country
8.5.2 Chart - MS Growth
8.6 Rapid and Point of Care - Rapid/POC 
8.6.1 Table Rapid/POC - by Country
8.6.2 Chart - Rapid/POC Growth 

9. Vision of the Future of AMR Diagnostics 

List of Tables
Table 1 USA - Outpatient Use of Antibiotics by Class
Table 2 USA - Outpatient Use of Antibiotics Top 5 
Table 3 Market Players by Type
Table 4 Known Human Pathogenic Diseases 
Table 5 The Key Market Opportunities
Table 6 Market Potential DRSP Diagnostic 
Table 7 Market Potential DRC Diagnostic
Table 8 Market Potential CD Diagnostic 
Table 9 Market Potential CD Diagnostic 
Table 10 Market Potential DRNG Diagnostic 
Table 11 Market Potential DRNTS Diagnostic
Table 12 Key AMR Diagnostics Issues 
Table 13 Global Market by Region 
Table 14 Global Market by Pathogen 
Table 15 Global Market by Technology 
Table 16 DRSP by Country 
Table 17 DRC by Country
Table 18 CD by Country
Table 19 MRSA by Country
Table 20 DRNG by Country
Table 21 DRNTS by Country
Table 22 Culture by Country
Table 23 Immunoassay by Country 
Table 24 PCR by Country 
Table 25 NGS by Country
Table 26 MS by Country 
Table 27 Rapid/POC by Country 

List of Figures
Figure 1 Pharmaceutical Spending History by Country 
Figure 2 AMR and Antibiotic Introduction
Figure 3 The Death Toll of AMR
Figure 4 Global Market Share Chart 
Figure 5 Global Market by Pathogen - Base vs. End Year
Figure 6 Global Market by Pathogen Base Year
Figure 7 Global Market by Pathogen End Year 
Figure 8 Pathogen Share by Year
Figure 9 Pathogen Segment Growth 
Figure 10 Technology - Base vs. End Year Segment Shift
Figure 11 Technology Market Base Year 
Figure 12 Technology Market End Year
Figure 13 Technology Share by Year
Figure 14 Technology Segment Growth 
Figure 15 DRSP Growth 
Figure 16 DRC Diagnostics Growth 
Figure 17 CD Growth 
Figure 18 MRSA Growth
Figure 19 DRNG Growth
Figure 20 DRNTS Growth
Figure 21 Culture Growth
Figure 22 Immunoassay Growth
Figure 23 PCR Growth 
Figure 24 NGS Growth
Figure 25 MS Growth 
Figure 26 Rapid/POC Growth